Proceedings of the 3rd annual albert institute for bladder cancer research symposium

Thomas W. Flaig, Ashish M. Kamat, Donna Hansel, Molly A. Ingersoll, H. Barton Grossman, Cathy Mendelsohn, David Degraff, Joseph C. Liao, John A. Taylor

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The Third Annual Albert Institute Bladder Symposium was held on September 8-10th, 2016, in Denver Colorado. Participants discussed several critical topics in the field of bladder cancer: 1) Best practices for tissue analysis and use to optimize correlative studies, 2) Modeling bladder cancer to facilitate understanding and innovation, 3) Targeted therapies for bladder cancer, 4) Tumor phylogeny in bladder cancer, 5) New Innovations in bladder cancer diagnostics. Our understanding of and approach to treating urothelial carcinoma is undergoing rapid advancement. Preclinical models of bladder cancer have been leveraged to increase our basic and mechanistic understanding of the disease. With the approval of immune checkpoint inhibitors for the treatment of advanced urothelial carcinoma, the treatment approach for these patients has quickly changed. In this light, molecularly-defined subtypes of bladder cancer and appropriate pre-clinical models are now essential to the further advancement and appropriate application of these therapeutic improvements. The optimal collection and processing of clinical urothelial carcinoma tissues samples will also be critical in the development of predictive biomarkers for therapeutic selection. Technological advances in other areas including optimal imaging technologies and micro/nanotechnologies are being applied to bladder cancer, especially in the localized setting, and hold the potential for translational impact in the treatment of bladder cancer patients. Taken together, advances in several basic science and clinical areas are now converging in bladder cancer. These developments hold the promise of shaping and improving the clinical care of those with the disease.

Original languageEnglish (US)
Pages (from-to)211-223
Number of pages13
JournalBladder Cancer
Volume3
Issue number3
DOIs
StatePublished - Jan 1 2017

Fingerprint

Urinary Bladder Neoplasms
Research
Carcinoma
Therapeutics
Benchmarking
Nanotechnology
Phylogeny
Urinary Bladder
Biomarkers
Technology

All Science Journal Classification (ASJC) codes

  • Oncology
  • Urology

Cite this

Flaig, T. W., Kamat, A. M., Hansel, D., Ingersoll, M. A., Barton Grossman, H., Mendelsohn, C., ... Taylor, J. A. (2017). Proceedings of the 3rd annual albert institute for bladder cancer research symposium. Bladder Cancer, 3(3), 211-223. https://doi.org/10.3233/BLC-170111
Flaig, Thomas W. ; Kamat, Ashish M. ; Hansel, Donna ; Ingersoll, Molly A. ; Barton Grossman, H. ; Mendelsohn, Cathy ; Degraff, David ; Liao, Joseph C. ; Taylor, John A. / Proceedings of the 3rd annual albert institute for bladder cancer research symposium. In: Bladder Cancer. 2017 ; Vol. 3, No. 3. pp. 211-223.
@article{f1a8ee62382c4bcfbee2eb88d491e1ac,
title = "Proceedings of the 3rd annual albert institute for bladder cancer research symposium",
abstract = "The Third Annual Albert Institute Bladder Symposium was held on September 8-10th, 2016, in Denver Colorado. Participants discussed several critical topics in the field of bladder cancer: 1) Best practices for tissue analysis and use to optimize correlative studies, 2) Modeling bladder cancer to facilitate understanding and innovation, 3) Targeted therapies for bladder cancer, 4) Tumor phylogeny in bladder cancer, 5) New Innovations in bladder cancer diagnostics. Our understanding of and approach to treating urothelial carcinoma is undergoing rapid advancement. Preclinical models of bladder cancer have been leveraged to increase our basic and mechanistic understanding of the disease. With the approval of immune checkpoint inhibitors for the treatment of advanced urothelial carcinoma, the treatment approach for these patients has quickly changed. In this light, molecularly-defined subtypes of bladder cancer and appropriate pre-clinical models are now essential to the further advancement and appropriate application of these therapeutic improvements. The optimal collection and processing of clinical urothelial carcinoma tissues samples will also be critical in the development of predictive biomarkers for therapeutic selection. Technological advances in other areas including optimal imaging technologies and micro/nanotechnologies are being applied to bladder cancer, especially in the localized setting, and hold the potential for translational impact in the treatment of bladder cancer patients. Taken together, advances in several basic science and clinical areas are now converging in bladder cancer. These developments hold the promise of shaping and improving the clinical care of those with the disease.",
author = "Flaig, {Thomas W.} and Kamat, {Ashish M.} and Donna Hansel and Ingersoll, {Molly A.} and {Barton Grossman}, H. and Cathy Mendelsohn and David Degraff and Liao, {Joseph C.} and Taylor, {John A.}",
year = "2017",
month = "1",
day = "1",
doi = "10.3233/BLC-170111",
language = "English (US)",
volume = "3",
pages = "211--223",
journal = "Bladder Cancer",
issn = "2352-3727",
publisher = "IOS Press",
number = "3",

}

Flaig, TW, Kamat, AM, Hansel, D, Ingersoll, MA, Barton Grossman, H, Mendelsohn, C, Degraff, D, Liao, JC & Taylor, JA 2017, 'Proceedings of the 3rd annual albert institute for bladder cancer research symposium', Bladder Cancer, vol. 3, no. 3, pp. 211-223. https://doi.org/10.3233/BLC-170111

Proceedings of the 3rd annual albert institute for bladder cancer research symposium. / Flaig, Thomas W.; Kamat, Ashish M.; Hansel, Donna; Ingersoll, Molly A.; Barton Grossman, H.; Mendelsohn, Cathy; Degraff, David; Liao, Joseph C.; Taylor, John A.

In: Bladder Cancer, Vol. 3, No. 3, 01.01.2017, p. 211-223.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Proceedings of the 3rd annual albert institute for bladder cancer research symposium

AU - Flaig, Thomas W.

AU - Kamat, Ashish M.

AU - Hansel, Donna

AU - Ingersoll, Molly A.

AU - Barton Grossman, H.

AU - Mendelsohn, Cathy

AU - Degraff, David

AU - Liao, Joseph C.

AU - Taylor, John A.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The Third Annual Albert Institute Bladder Symposium was held on September 8-10th, 2016, in Denver Colorado. Participants discussed several critical topics in the field of bladder cancer: 1) Best practices for tissue analysis and use to optimize correlative studies, 2) Modeling bladder cancer to facilitate understanding and innovation, 3) Targeted therapies for bladder cancer, 4) Tumor phylogeny in bladder cancer, 5) New Innovations in bladder cancer diagnostics. Our understanding of and approach to treating urothelial carcinoma is undergoing rapid advancement. Preclinical models of bladder cancer have been leveraged to increase our basic and mechanistic understanding of the disease. With the approval of immune checkpoint inhibitors for the treatment of advanced urothelial carcinoma, the treatment approach for these patients has quickly changed. In this light, molecularly-defined subtypes of bladder cancer and appropriate pre-clinical models are now essential to the further advancement and appropriate application of these therapeutic improvements. The optimal collection and processing of clinical urothelial carcinoma tissues samples will also be critical in the development of predictive biomarkers for therapeutic selection. Technological advances in other areas including optimal imaging technologies and micro/nanotechnologies are being applied to bladder cancer, especially in the localized setting, and hold the potential for translational impact in the treatment of bladder cancer patients. Taken together, advances in several basic science and clinical areas are now converging in bladder cancer. These developments hold the promise of shaping and improving the clinical care of those with the disease.

AB - The Third Annual Albert Institute Bladder Symposium was held on September 8-10th, 2016, in Denver Colorado. Participants discussed several critical topics in the field of bladder cancer: 1) Best practices for tissue analysis and use to optimize correlative studies, 2) Modeling bladder cancer to facilitate understanding and innovation, 3) Targeted therapies for bladder cancer, 4) Tumor phylogeny in bladder cancer, 5) New Innovations in bladder cancer diagnostics. Our understanding of and approach to treating urothelial carcinoma is undergoing rapid advancement. Preclinical models of bladder cancer have been leveraged to increase our basic and mechanistic understanding of the disease. With the approval of immune checkpoint inhibitors for the treatment of advanced urothelial carcinoma, the treatment approach for these patients has quickly changed. In this light, molecularly-defined subtypes of bladder cancer and appropriate pre-clinical models are now essential to the further advancement and appropriate application of these therapeutic improvements. The optimal collection and processing of clinical urothelial carcinoma tissues samples will also be critical in the development of predictive biomarkers for therapeutic selection. Technological advances in other areas including optimal imaging technologies and micro/nanotechnologies are being applied to bladder cancer, especially in the localized setting, and hold the potential for translational impact in the treatment of bladder cancer patients. Taken together, advances in several basic science and clinical areas are now converging in bladder cancer. These developments hold the promise of shaping and improving the clinical care of those with the disease.

UR - http://www.scopus.com/inward/record.url?scp=85050932762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050932762&partnerID=8YFLogxK

U2 - 10.3233/BLC-170111

DO - 10.3233/BLC-170111

M3 - Article

C2 - 28824949

AN - SCOPUS:85050932762

VL - 3

SP - 211

EP - 223

JO - Bladder Cancer

JF - Bladder Cancer

SN - 2352-3727

IS - 3

ER -

Flaig TW, Kamat AM, Hansel D, Ingersoll MA, Barton Grossman H, Mendelsohn C et al. Proceedings of the 3rd annual albert institute for bladder cancer research symposium. Bladder Cancer. 2017 Jan 1;3(3):211-223. https://doi.org/10.3233/BLC-170111